Latest & greatest articles for insomnia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insomnia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insomnia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insomnia

21. The efficacy and safety of stimulating on single acupoint Sanyinjiao (SP 6) for managing insomnia: a systematic review of randomized controlled trials

The efficacy and safety of stimulating on single acupoint Sanyinjiao (SP 6) for managing insomnia: a systematic review of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

22. Deprescribing of chronic benzodiazepine receptor agonists for insomnia in adults [Cochrane protocol]

Deprescribing of chronic benzodiazepine receptor agonists for insomnia in adults [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

23. In clinical and community-based samples (P), do insomnia and/or sleep disturbances (E) predict child and youth depression (O) compared to typical sleep (C)? A systematic review and meta-analysis

In clinical and community-based samples (P), do insomnia and/or sleep disturbances (E) predict child and youth depression (O) compared to typical sleep (C)? A systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

24. Paradoxical intention for insomnia: a systematic review and meta-analysis

Paradoxical intention for insomnia: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

25. Effectiveness of Traditional Chinese medicine for insomnia in patients with hypertension: a systematic review

Effectiveness of Traditional Chinese medicine for insomnia in patients with hypertension: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

26. Therapeutic efficacy of zolpidem combined with cognitive behavioral therapy (CBT) on primary insomnia (PI): a protocol of systematic review

Therapeutic efficacy of zolpidem combined with cognitive behavioral therapy (CBT) on primary insomnia (PI): a protocol of systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

27. Non-invasive brain stimulation to treat insomnia and sleep quality

Non-invasive brain stimulation to treat insomnia and sleep quality Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

28. Pharmacologic treatment for primary insomnia in adults: a systematic review and network meta-analysis

Pharmacologic treatment for primary insomnia in adults: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

29. Economic evaluation of cognitive behavioural therapy for insomnia (CBT-I) for improving health outcomes in adult population: a systematic review protocol

Economic evaluation of cognitive behavioural therapy for insomnia (CBT-I) for improving health outcomes in adult population: a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

30. Effect of Traditional East Asian Medicinal herbal tea (HT002) on insomnia: a randomized controlled pilot study. (PubMed)

Effect of Traditional East Asian Medicinal herbal tea (HT002) on insomnia: a randomized controlled pilot study. Complementary and alternative medicine treatment for insomnia has been sought due to the possible adverse effects of conventional pharmacotherapies. We performed a preliminary evaluation of the feasibility of using, and of the effect of a herbal tea (HT002), based on Traditional East Asian Medicine, in mild-to-moderate insomnia.Patients (n = 40) with mild-to-moderate insomnia were (...) randomized to the HT002 (n = 20) or waitlist (n = 20) groups. The HT002 group consumed HT002 twice daily for 4 weeks. Outcomes were assessed using the Insomnia Severity Scale (ISI), Pittsburgh Sleep Quality Index (PSQI), and 12-item Short Form Health Survey (SF-12) at baseline and after 4 and 8 weeks.The ISI score differences from baseline at weeks 4 and 8 were significantly greater in the HT002 than that in the waitlist group (week 4: -4.0 ± 0.8 vs. -0.4 ± 0.8, p < 0.05; week 8: -4.8 ± 0.7 vs. -0.9

Full Text available with Trip Pro

2019 Integrative medicine research Controlled trial quality: uncertain

31. Combined electroacupuncture and auricular acupuncture for primary insomnia: a randomised controlled trial of dose-response effect. (PubMed)

Combined electroacupuncture and auricular acupuncture for primary insomnia: a randomised controlled trial of dose-response effect. 30674705 2019 01 24 1024-2708 25 Suppl 2 2019 Feb Hong Kong medical journal = Xianggang yi xue za zhi Hong Kong Med J Combined electroacupuncture and auricular acupuncture for primary insomnia: a randomised controlled trial of dose-response effect. 28-33 Chung K F KF Department of Psychiatry, The University of Hong Kong. Yeung W F WF School of Chinese Medicine

2019 Hong Kong medical journal = Xianggang yi xue za zhi Controlled trial quality: uncertain

32. Effects of a digital therapy (Sleepio) for the treatment of insomnia: a collaborative individual participant data meta-analysis of randomised controlled trials

Effects of a digital therapy (Sleepio) for the treatment of insomnia: a collaborative individual participant data meta-analysis of randomised controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

33. A meta-analysis of relationship between insomnia and functional gastrointestinal disorder

A meta-analysis of relationship between insomnia and functional gastrointestinal disorder Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

34. Effective? Engaging? Secure? Applying the ORCHA-24 framework to evaluate apps for chronic insomnia disorder

Effective? Engaging? Secure? Applying the ORCHA-24 framework to evaluate apps for chronic insomnia disorder Effective? Engaging? Secure? Applying the ORCHA-24 framework to evaluate apps for chronic insomnia disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Effective? Engaging? Secure? Applying the ORCHA-24 framework to evaluate apps for chronic insomnia disorder Article Text Original article Effective? Engaging? Secure? Applying

2018 Evidence-Based Mental Health

35. Eszopiclone for insomnia. (PubMed)

Eszopiclone for insomnia. Insomnia is a major public health issue affecting between 6% to 10% of the adult population in Western countries. Eszopiclone is a hypnotic drug belonging to a newer group of hypnotic agents, known as new generation hypnotics, which was marketed as being just as effective as benzodiazepines for this condition, while being safer and having a lower risk for abuse and dependence. It is the aim of the review to integrate evidence from randomised controlled trials (...) and to draw conclusions on eszopiclone's efficacy and safety profile, while taking methodological features and bias risks into consideration.To assess the efficacy and safety of eszopiclone for the treatment of insomnia compared to placebo or active control.We searched the Cochrane Central Register of Controlled trials (CENTRAL), MEDLINE, Embase, PsycINFO, PSYNDEX and registry databases (WHO trials portal, ClinicalTrials.gov) with results incorporated from searches to 10 February 2016. To identify trials

2018 Cochrane

36. Melatonin (Slenyto) - insomnia (difficulty sleeping) in children and adolescents (2 to 18 years old)

Melatonin (Slenyto) - insomnia (difficulty sleeping) in children and adolescents (2 to 18 years old) Slenyto | European Medicines Agency Search Search Menu Slenyto melatonin Table of contents Authorised This medicine is authorised for use in the European Union. Overview Slenyto is a medicine for treating insomnia (difficulty sleeping) in children and adolescents (2 to 18 years old) who have: autism spectrum disorder (ASD), a range of conditions that affects the patient’s social interactions (...) areas of the brain and helping to bring about sleep. Its levels in the blood normally increase after the onset of darkness and peak in the middle of the night. Patients with developmental conditions may produce less melatonin, leading to the development of insomnia. Slenyto increases levels of melatonin in the blood, helping them to sleep. Because Slenyto releases melatonin slowly over a few hours, it mimics the natural production of melatonin in the body. What benefits of Slenyto have been shown

2018 European Medicines Agency - EPARs

37. Insomnia

Insomnia Top results for insomnia - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for insomnia The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

38. Impact of group treatment for insomnia on daytime symptomatology: Analyses from a randomized controlled trial in primary care

Impact of group treatment for insomnia on daytime symptomatology: Analyses from a randomized controlled trial in primary care People typically seek primary health care for daytime symptoms and impairments they experience in association with their insomnia. However, few studies address the question of whether insomnia treatment can improve such symptomatology.To investigate whether a nurse-led group treatment program, based on the techniques of cognitive behavioral therapy for insomnia (CBT-I (...) ), improved daytime symptomatology in primary care patients with insomnia.Fatigue (Fatigue Severity Scale [FSS]; main outcome), mood (General Health Questionnaire and Montgomery-Asberg Depression Rating Scale), health-related quality of life (Short-Form Health Survey), general daytime functioning, specific daytime symptoms (individual items from the Insomnia Severity Index and Uppsala Sleep Inventory), and dysfunctional beliefs (Dysfunctional Beliefs and Attitudes about Sleep).A randomized controlled

Full Text available with Trip Pro

2018 EvidenceUpdates

39. Antidepressants for insomnia in adults. (PubMed)

Antidepressants for insomnia in adults. Insomnia disorder is a subjective condition of unsatisfactory sleep (e.g. sleep onset, maintenance, early waking, impairment of daytime functioning). Insomnia disorder impairs quality of life and is associated with an increased risk of physical and mental health problems including anxiety, depression, drug and alcohol abuse, and increased health service use. hypnotic medications (e.g. benzodiazepines and 'Z' drugs) are licensed for sleep promotion (...) , but can induce tolerance and dependence, although many people remain on long-term treatment. Antidepressant use for insomnia is widespread, but none is licensed for insomnia and the evidence for their efficacy is unclear. This use of unlicensed medications may be driven by concern over longer-term use of hypnotics and the limited availability of psychological treatments.To assess the effectiveness, safety and tolerability of antidepressants for insomnia in adults.This review incorporated the results

Full Text available with Trip Pro

2018 Cochrane

40. Benefits and Harms of Cranial Electrical Stimulation for Chronic Painful Conditions, Depression, Anxiety, and Insomnia: A Systematic Review. (PubMed)

Benefits and Harms of Cranial Electrical Stimulation for Chronic Painful Conditions, Depression, Anxiety, and Insomnia: A Systematic Review. Cranial electrical stimulation (CES) is increasingly popular as a treatment, yet its clinical benefit is unclear.To review evidence about the benefits and harms of CES for adult patients with chronic painful conditions, depression, anxiety, and insomnia.Several databases from inception to 10 October 2017 without language restrictions and references from (...) with insomnia (n = 2), insomnia and anxiety (n = 1), or depression (n = 3) had inconclusive or conflicting results. Low-strength evidence suggested that CES does not cause serious side effects.Most trials had small sample sizes and short durations; all had high risk of bias due to inadequate blinding.Evidence is insufficient that CES has clinically important effects on fibromyalgia, headache, neuromusculoskeletal pain, degenerative joint pain, depression, or insomnia; low-strength evidence suggests modest

2018 Annals of Internal Medicine